|
Clinical Trials and Observations
Citations 361-370 of 2742 total displayed.
|
Past content
(since May 1998):
|
Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia
- Constantine S. Tam, Hagop Kantarjian, Guillermo Garcia-Manero, Gautam Borthakur, Susan O'Brien, Farhad Ravandi, Jenny Shan, and Jorge Cortes
Blood 2008; 112: 516-518.
[Abstract]
[Full text]
[PDF]
WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)
- Emilio Paolo Alessandrino, Matteo Giovanni Della Porta, Andrea Bacigalupo, Maria Teresa Van Lint, Michele Falda, Francesco Onida, Massimo Bernardi, Anna Paola Iori, Alessandro Rambaldi, Raffaella Cerretti, Paola Marenco, Pietro Pioltelli, Luca Malcovati, Cristiana Pascutto, Rosi Oneto, Renato Fanin, and Alberto Bosi
Blood 2008; 112: 895-902.
[Abstract]
[Full text]
[PDF]
The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal
- Jerry L. Spivak and Richard T. Silver
Blood 2008; 112: 231-239.
[Full text]
[PDF]
Acquired factor VIII inhibitors
- Massimo Franchini and Giuseppe Lippi
Blood 2008; 112: 250-255.
[Abstract]
[Full text]
[PDF]
Common variable immunodeficiency disorders: division into distinct clinical phenotypes
- Helen Chapel, Mary Lucas, Martin Lee, Janne Bjorkander, David Webster, Bodo Grimbacher, Claire Fieschi, Vojtech Thon, Mohammad R. Abedi, and Lennart Hammarstrom
Blood 2008; 112: 277-286.
[Abstract]
[Full text]
[PDF]
Idiopathic CD4+ lymphocytopenia: natural history and prognostic factors
- Dimitrios I. Zonios, Judith Falloon, John E. Bennett, Pamela A. Shaw, Doreen Chaitt, Michael W. Baseler, Joseph W. Adelsberger, Julia A. Metcalf, Michael A. Polis, Stephen J. Kovacs, Joseph A. Kovacs, Richard T. Davey, H. Clifford Lane, Henry Masur, and Irini Sereti
Blood 2008; 112: 287-294.
[Abstract]
[Full text]
[PDF]
Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: particular activity against advanced hematologic malignancies
- Reinhard Marks, Karin Potthoff, Joachim Hahn, Gabriele Ihorst, Hartmut Bertz, Alexandros Spyridonidis, Ernst Holler, and Jürgen M. Finke
Blood 2008; 112: 415-425.
[Abstract]
[Full text]
[PDF]
Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission
- David I. Marks, Waleska S. Pérez, Wensheng He, Mei-Jie Zhang, Michael R. Bishop, Brian J. Bolwell, Christopher N. Bredeson, Edward A. Copelan, Robert Peter Gale, Vikas Gupta, Gregory A. Hale, Luis M. Isola, Ann A. Jakubowski, Armand Keating, Thomas R. Klumpp, Hillard M. Lazarus, Jane L. Liesveld, Richard T. Maziarz, Philip L. McCarthy, Mitchell Sabloff, Gary Schiller, Jorge Sierra, Martin S. Tallman, Edmund K. Waller, Peter H. Wiernik, and Daniel J. Weisdorf
Blood 2008; 112: 426-434.
[Abstract]
[Full text]
[PDF]
Investment analysts and the American Society of Hematology
- David P. Steensma
Blood 2008; 112: 29-33.
[Abstract]
[Full text]
[PDF]
Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs
- Dana E. Rollison, Nadia Howlader, Martyn T. Smith, Sara S. Strom, William D. Merritt, Lynn A. Ries, Brenda K. Edwards, and Alan F. List
Blood 2008; 112: 45-52.
[Abstract]
[Full text]
[PDF]
|
|
